- Trial phase
- Approved (FDA, Apr 2025). Locally tracked clinical data shows a completed Phase 2 atrasentan study in IgA nephropathy (N
- Time to market
- Already on the market, FDA approval catalyst recorded 2025-04-02.
- Why 3/10
- Vanrafia's defining binary already passed, FDA approval recorded 2025-04-02, and no new PDUFA/pivotal readout for it is scheduled in the next ~12 months (no upcoming FDA catalysts for NVS in local data), so per the rubric an approved, commercializing product that is a small part of a ~$285B portfolio scores 3, not higher.
Watch quarterly 6-Ks for Vanrafia's first full-year sales trajectory and any label-expansion or new atrasentan readouts (the Phase 2 crossover study completed Oct 2025, so a publication/next-trial update could come). But treat Vanrafia as immaterial to NVS's share price, the stock trades on the broader portfolio (Kisqali/Pluvicto growth, Entresto generic erosion, pipeline catalysts), not on this single niche product.
Price Chart
Executive Summary
Vanrafia (atrasentan) is Novartis's oral endothelin-A receptor antagonist for IgA nephropathy, approved by the FDA on April 2, 2025; the local stock-price history shows a modest +2.42% one-day move around that approval. A June 2026 FDA safety-labeling action added a boxed embryo-fetal toxicity warning (contraindicated in pregnancy, contraception required). Vanrafia is one of 30+ products listed in Novartis's Q2 2026 earnings report and is not among the company's headline growth drivers, so for investors it is a minor, already-approved product inside a ~$285B-cap diversified pharma.
How It Works
Atrasentan (Vanrafia) is an endothelin-A receptor antagonist: it blocks the action of endothelin-1, a signaling protein that constricts blood vessels and promotes inflammation and scarring in the kidney. In IgA nephropathy (a disease where antibody deposits damage the kidneys' filters), this reduces protein leaking into the urine and helps slow loss of kidney function. It is taken by mouth.
Trial Status
A randomized, double-blind, placebo-controlled Phase 2 crossover study of atrasentan in IgA nephropathy (NCT05834738) is COMPLETED: started Jul 2023, primary completion Jun 2025, completion Oct 2025, enrollment 54, with results available per the ClinicalTrials.gov record. The FDA approval catalyst for Vanrafia is dated 2025-04-02, and a June 2026 FDA safety-labeling action added an embryo-fetal toxicity boxed warning.
The Two-Sided Case
Upcoming Catalysts
- No FDA catalysts for Vanrafia scheduled in the next 90 days (local data)
- Quarterly earnings 6-Ks (next: Q3 2026) disclosing Vanrafia sales ramp
- Potential publication/presentation of completed atrasentan Phase 2 data (NCT05834738, completed Oct 2025) or a next-phase program update
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report